Literature DB >> 22175713

Synthesis, biological evaluation, and radioiodination of halogenated closo-carboranylthymidine analogues.

Rohit Tiwari1, Antonio Toppino, Hitesh K Agarwal, Tianyao Huo, Youngjoo Byun, Judith Gallucci, Sherifa Hasabelnaby, Ahmed Khalil, Ayman Goudah, Robert A Baiocchi, Michael V Darby, Rolf F Barth, Werner Tjarks.   

Abstract

The synthesis and initial biological evaluation of 3-carboranylthymidine analogues (3CTAs) that are (radio)halogenated at the closo-carborane cluster are described. Radiohalogenated 3CTAs have the potential to be used in the radiotherapy and imaging of cancer because they may be selectively entrapped in tumor cells through monophosphorylation by human thymidine kinase 1 (hTK1). Two strategies for the synthesis of a (127)I-labeled form of a specific 3CTA, previously designated as N5, are described: (1) direct iodination of N5 with iodine monochloride and aluminum chloride to obtain N5-(127)I and (2) initial monoiodination of o-carborane to 9-iodo-o-carborane followed by its functionalization to N5-(127)I. The former strategy produced N5-(127)I in low yields along with di-, tri-, and tetraiodinated N5 as well as decomposition products, whereas the latter method produced only N5-(127)I in high yields. N5-(127)I was subjected to nucleophilic halogen- and isotope-exchange reactions using Na(79/81)Br and Na(125)I, respectively, in the presence of Herrmann's catalyst to obtain N5-(79/81)Br and N5-(125)I, respectively. Two intermediate products formed using the second strategy, 1-(tert-butyldimethylsilyl)-9-iodo-o-carborane and 1-(tert-butyldimethylsilyl)-12-iodo-o-carborane, were subjected to X-ray diffraction studies to confirm that substitution at a single carbon atom of 9-iodo-o-carborane resulted in the formation of two structural isomers. To the best of our knowledge, this is the first report of halogen- and isotope-exchange reactions of B-halocarboranes that have been conjugated to a complex biomolecule. Human TK1 phosphorylation rates of N5, N5-(127)I, and N5-(79/81)Br ranged from 38.0% to 29.6% relative to that of thymidine, the endogenous hTK1 substrate. The in vitro uptake of N5, N5-(127)I, and N5-(79/81)Br in L929 TK1(+) cells was 2.0, 1.8, and 1.4 times greater than that in L929 TK1(-) cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22175713      PMCID: PMC3257809          DOI: 10.1021/ic202150b

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  36 in total

1.  The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling.

Authors:  Konstantin Arnold; Lorenza Bordoli; Jürgen Kopp; Torsten Schwede
Journal:  Bioinformatics       Date:  2005-11-13       Impact factor: 6.937

2.  Kinase-mediated trapping of bi-functional conjugates of paclitaxel or vinblastine with thymidine in cancer cells.

Authors:  Simon E Aspland; Carlo Ballatore; Rosario Castillo; Joel Desharnais; Trisha Eustaquio; Philip Goelet; Zijian Guo; Qing Li; David Nelson; Chengzao Sun; Angelo J Castellino; Michael J Newman
Journal:  Bioorg Med Chem Lett       Date:  2006-07-25       Impact factor: 2.823

3.  Charge dependent substrate activity of C3' and N3 functionalized, organometallic technetium and rhenium-labeled thymidine derivatives toward human thymidine kinase 1.

Authors:  Harriet Struthers; David Viertl; Marek Kosinski; Bernhard Spingler; Franz Buchegger; Roger Schibli
Journal:  Bioconjug Chem       Date:  2010-04-21       Impact factor: 4.774

4.  Hydrophilically enhanced 3-carboranyl thymidine analogues (3CTAs) for boron neutron capture therapy (BNCT) of cancer.

Authors:  Sureshbabu Narayanasamy; B T S Thirumamagal; Jayaseharan Johnsamuel; Youngjoo Byun; Ashraf S Al-Madhoun; Elena Usova; Guirec Y Cosquer; Junhua Yan; Achintya K Bandyopadhyaya; Rohit Tiwari; Staffan Eriksson; Werner Tjarks
Journal:  Bioorg Med Chem       Date:  2006-07-10       Impact factor: 3.641

Review 5.  Boron neutron capture therapy of cancer: current status and future prospects.

Authors:  Rolf F Barth; Jeffrey A Coderre; M Graça H Vicente; Thomas E Blue
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

6.  Human thymidine kinase 2: molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates.

Authors:  L Wang; B Munch-Petersen; A Herrström Sjöberg; U Hellman; T Bergman; H Jörnvall; S Eriksson
Journal:  FEBS Lett       Date:  1999-01-25       Impact factor: 4.124

7.  Polyborane reactions in ionic liquids: new efficient routes to functionalized decaborane and o-carborane clusters.

Authors:  Upal Kusari; Yuqi Li; Mark G Bradley; Larry G Sneddon
Journal:  J Am Chem Soc       Date:  2004-07-21       Impact factor: 15.419

8.  Evaluation of human thymidine kinase 1 substrates as new candidates for boron neutron capture therapy.

Authors:  Ashraf S Al-Madhoun; Jayaseharan Johnsamuel; Rolf F Barth; Werner Tjarks; Staffan Eriksson
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

9.  Boron-containing nucleosides as potential delivery agents for neutron capture therapy of brain tumors.

Authors:  Rolf F Barth; Weilian Yang; Ashraf S Al-Madhoun; Jayaseharan Johnsamuel; Youngjoo Byun; Subhash Chandra; Duane R Smith; Werner Tjarks; Staffan Eriksson
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

10.  Interleukin-13 receptors on human prostate carcinoma cell lines represent a novel target for a chimeric protein composed of IL-13 and a mutated form of Pseudomonas exotoxin.

Authors:  A Maini; G Hillman; G P Haas; C Y Wang; E Montecillo; F Hamzavi; J E Pontes; P Leland; I Pastan; W Debinski; R K Puri
Journal:  J Urol       Date:  1997-09       Impact factor: 7.600

View more
  7 in total

1.  Iodine monochloride facilitated deglycosylation, anomerization, and isomerization of 3-substituted thymidine analogues.

Authors:  Ahmed Khalil; Keisuke Ishita; Tehane Ali; Rohit Tiwari; Ramy Riachy; Antonio Toppino; Sherifa Hasabelnaby; Naum Sayfullin; Allen G Oliver; Judith Gallucci; Zhenguo Huang; Werner Tjarks
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2014       Impact factor: 1.381

2.  Synthesis and evaluation of thymidine kinase 1-targeting carboranyl pyrimidine nucleoside analogs for boron neutron capture therapy of cancer.

Authors:  Hitesh K Agarwal; Ahmed Khalil; Keisuke Ishita; Weilian Yang; Robin J Nakkula; Lai-Chu Wu; Tehane Ali; Rohit Tiwari; Youngjoo Byun; Rolf F Barth; Werner Tjarks
Journal:  Eur J Med Chem       Date:  2015-05-27       Impact factor: 6.514

Review 3.  N3-substituted thymidine bioconjugates for cancer therapy and imaging.

Authors:  Ahmed Khalil; Keisuke Ishita; Tehane Ali; Werner Tjarks
Journal:  Future Med Chem       Date:  2013-04       Impact factor: 3.808

4.  Synthesis of N3-substituted carboranyl thymidine bioconjugates and their evaluation as substrates of recombinant human thymidine kinase 1.

Authors:  Hitesh K Agarwal; Craig A McElroy; Elena Sjuvarsson; Staffan Eriksson; Michael V Darby; Werner Tjarks
Journal:  Eur J Med Chem       Date:  2012-12-05       Impact factor: 6.514

5.  Synthesis, chemical and enzymatic hydrolysis, and aqueous solubility of amino acid ester prodrugs of 3-carboranyl thymidine analogs for boron neutron capture therapy of brain tumors.

Authors:  Sherifa Hasabelnaby; Ayman Goudah; Hitesh K Agarwal; Mosaad S M abd Alla; Werner Tjarks
Journal:  Eur J Med Chem       Date:  2012-07-27       Impact factor: 6.514

6.  Biodistribution and subcellular localization of an unnatural boron-containing amino acid (cis-ABCPC) by imaging secondary ion mass spectrometry for neutron capture therapy of melanomas and gliomas.

Authors:  Subhash Chandra; Rolf F Barth; Syed A Haider; Weilian Yang; Tianyao Huo; Aarif L Shaikh; George W Kabalka
Journal:  PLoS One       Date:  2013-09-18       Impact factor: 3.240

7.  Utilization of Boron Compounds for the Modification of Suberoyl Anilide Hydroxamic Acid as Inhibitor of Histone Deacetylase Class II Homo sapiens.

Authors:  Ridla Bakri; Arli Aditya Parikesit; Cipta Prio Satriyanto; Djati Kerami; Usman Sumo Friend Tambunan
Journal:  Adv Bioinformatics       Date:  2014-08-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.